|View printer-friendly version|
|August 14, 2001 11:37 a.m.|
|Teva Wins Nabumetone Lawsuit Will Commence Sales of Generic Equivalent of Relafen® Immediately|
Jerusalem, Israel, August 14, 2001 - Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA) announced today that it has won the lawsuit brought against it by SmithKline Beecham regarding the U.S. patent covering Nabumetone, the active ingredient in Relafen®. Teva's U.S. subsidiary expects to commence sales of Nabumetone immediately. Annual sales of the branded product in the U.S. during the twelve months ended June 30, 2001, were estimated to be approximately $266 million. As the first applicant to challenge the listed patent for this drug, Teva is entitled to a 180-day period of generic marketing exclusivity.